Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Reviva Pharmaceuticals Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CUPERTINO, CALIF., OCT. 28, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT NEGATIVE SYMPTOM DATA FOR BRILAROXAZINE FROM THE PHASE 3 RECOVER DOUBLE-BLIND TRIAL IN PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA, AND FROM THE LONG-TERM OPEN-LABEL EXTENSION TRIAL IN CLINICALLY STABLE SCHIZOPHRENIA PATIENTS WILL BE PRESENTED AS A POSTER PRESENTATION AT THE CNS SUMMIT 2025, TAKING PLACE NOVEMBER 2-5, IN BOSTON, MASSACHUSETTS.

REVIVA TO PRESENT NEGATIVE SYMPTOM DATA FOR BRILAROXAZINE IN SCHIZOPHRENIA FROM THE PHASE 3 RECOVER DOUBLE-BLIND AND OPEN-LABEL EXTENSION TRIALS AT THE CNS SUMMIT 2025

CUPERTINO, CALIF., OCT. 07, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT LAXMINARAYAN BHAT, PHD, FOUNDER, PRESIDENT, AND CEO OF REVIVA WILL PARTICIPATE IN A FIRESIDE CHAT AND KEY OPINION LEADER (KOL) WEBINAR HOSTED BY A.G.P./ALLIANCE GLOBAL PARTNERS ON OCTOBER 10, 2025 AT 11:00 AM ET.

REVIVA TO PARTICIPATE IN KEY OPINION LEADER WEBINAR HOSTED BY ALLIANCE GLOBAL PARTNERS

CUPERTINO, CALIF., SEPT. 18, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING WITH EXISTING AND NEW HEALTHCARE FOCUSED INSTITUTIONAL INVESTORS FOR THE PURCHASE AND SALE OF 27,000,000 SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) TOGETHER WITH SERIES E WARRANTS TO PURCHASE UP TO 27,000,000 SHARES OF COMMON STOCK (THE "SERIES E WARRANTS") AND SERIES F WARRANTS TO PURCHASE UP TO 27,000,000 SHARES OF COMMON STOCK (THE "SERIES F WARRANTS"), AT A COMBINED OFFERING PRICE OF $0.335 PER SHARE AND ACCOMPANYING WARRANTS, FOR AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $9 MILLION BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES.

REVIVA PHARMACEUTICALS HOLDINGS, INC. ANNOUNCES PRICING OF $9 MILLION PUBLIC OFFERING

CUPERTINO, CALIF., SEPT. 18, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT IT INTENDS TO OFFER SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK IN A PUBLIC OFFERING. ALL OF THE SECURITIES TO BE SOLD IN THE OFFERING ARE TO BE OFFERED BY REVIVA. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

REVIVA PHARMACEUTICALS HOLDINGS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING

 WELL-TOLERATED SAFETY PROFILE AND ROBUST BROAD-SPECTRUM EFFICACY SUSTAINED OVER 1-YEAR ACROSS ALL SYMPTOM DOMAINS INCLUDING NEGATIVE SYMPTOMS IN OPEN LABEL EXTENSION (OLE) 1-YEAR TRIAL

REVIVA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

CUPERTINO, CALIF., JUNE 26, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING WITH EXISTING AND NEW HEALTHCARE FOCUSED INSTITUTIONAL INVESTORS FOR THE PURCHASE AND SALE OF 20,000,000 SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) TOGETHER WITH SERIES C WARRANTS TO PURCHASE UP TO 20,000,000 SHARES OF COMMON STOCK (THE "SERIES C WARRANTS") AND SERIES D WARRANTS TO PURCHASE UP TO 20,000,000 SHARES OF COMMON STOCK (THE "SERIES D WARRANTS"), AT A COMBINED OFFERING PRICE OF $0.50 PER SHARE AND ACCOMPANYING WARRANTS, FOR AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $10 MILLION BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES.

REVIVA PHARMACEUTICALS HOLDINGS, INC. ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING

CUPERTINO, CALIF., JUNE 25, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT IT INTENDS TO OFFER SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK IN A PUBLIC OFFERING. ALL OF THE SECURITIES TO BE SOLD IN THE OFFERING ARE TO BE OFFERED BY REVIVA. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

CUPERTINO, CALIF., JUNE 05, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH) (REVIVA OR THE COMPANY), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT LAXMINARAYAN BHAT, PH.D., FOUNDER, PRESIDENT, AND CEO OF REVIVA WILL PRESENT AT THE H.C. WAINWRIGHT 6TH ANNUAL NEURO PERSPECTIVES HYBRID CONFERENCE, TAKING PLACE JUNE 16-17, 2025.

REVIVA TO PARTICIPATE IN THE H.C. WAINWRIGHT 6TH ANNUAL NEURO PERSPECTIVES HYBRID CONFERENCE

 ROBUST BROAD-SPECTRUM EFFICACY SUSTAINED OVER 1-YEAR ACROSS ALL SYMPTOM DOMAINS INCLUDING NEGATIVE SYMPTOMS   GENERALLY WELL-TOLERATED WITH LOW RATES OF ADVERSE EVENTS AND DISCONTINUATION   BRILAROXAZINE IMPROVED MULTIPLE NEUROINFLAMMATORY MARKERS REPORTED TO ENHANCE EFFICACY AND MITIGATE SIDE EFFECTS   VIRTUAL INVESTOR WEBCAST TODAY AT 8:00 A.M. EDT  CUPERTINO, CALIF.

REVIVA ANNOUNCES POSITIVE FULL DATASET FOR 1-YEAR PHASE 3 RECOVER OPEN LABEL EXTENSION STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA

 446 PARTICIPANTS COMPLETED THE BRILAROXAZINE LONG-TERM OPEN-LABEL EXTENSION (OLE) TRIAL WITH 156 COMPLETING ONE-YEAR AND 301 COMPLETING SIX MONTHS OF TREATMENT 

REVIVA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

CUPERTINO, CALIF., MARCH 30, 2025 (GLOBE NEWSWIRE) -- REVIVA PHARMACEUTICALS HOLDINGS, INC. (NASDAQ: RVPH), A LATE-STAGE PHARMACEUTICAL COMPANY DEVELOPING THERAPIES THAT SEEK TO ADDRESS UNMET MEDICAL NEEDS IN THE AREAS OF CENTRAL NERVOUS SYSTEM (CNS), INFLAMMATORY AND CARDIOMETABOLIC DISEASES, ANNOUNCED TODAY TOPLINE DATA FROM THE LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA WILL BE PRESENTED AS PART OF AN ORAL PRESENTATION AT THE 2025 CONGRESS OF THE SCHIZOPHRENIA INTERNATIONAL RESEARCH SOCIETY (SIRS) TAKING PLACE MARCH 29 TO APRIL 2, 2025 IN CHICAGO, ILLINOIS, U.S.

Reviva Pharmaceuticals Holdings, Inc.

RVPH

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Reviva Pharmaceuticals Holdings, Inc.

RVPH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RVPH